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Abstract
Epidemiological studies support a strong association between high-density lipo-
protein (HDL) cholesterol levels and heart failure incidence. Experimental evi-
dence from different angles supports the view that low HDL is unlikely an
innocent bystander in the development of heart failure. HDL exerts direct
cardioprotective effects, which are mediated via its interactions with the myocar-
dium and more specifically with cardiomyocytes. HDL may improve cardiac
function in several ways. Firstly, HDL may protect the heart against ischaemia/
reperfusion injury resulting in a reduction of infarct size and thus in myocardial
salvage. Secondly, HDL can improve cardiac function in the absence of
ischaemic heart disease as illustrated by beneficial effects conferred by these
lipoproteins in diabetic cardiomyopathy. Thirdly, HDL may improve cardiac
function by reducing infarct expansion and by attenuating ventricular
remodelling post-myocardial infarction. These different mechanisms are
substantiated by in vitro, ex vivo, and in vivo intervention studies that applied
treatment with native HDL, treatment with reconstituted HDL, or human apo A-I
gene transfer. The effect of human apo A-I gene transfer on infarct expansion and
ventricular remodelling post-myocardial infarction illustrates the beneficial
effects of HDL on tissue repair. The role of HDL in tissue repair is further
underpinned by the potent effects of these lipoproteins on endothelial progenitor
cell number, function, and incorporation, which may in particular be relevant
under conditions of high endothelial cell turnover. Furthermore, topical HDL
therapy enhances cutaneous wound healing in different models. In conclusion,
the development of HDL-targeted interventions in these strategically chosen
therapeutic areas is supported by a strong clinical rationale and significant
preclinical data.
Keywords
High-density lipoproteins • Apolipoprotein A-I • Heart failure • Ventricular
remodelling • Drug development • Ischaemia/reperfusion injury • Tissue repair •
Wound healing • Diabetic ulcer
Abbreviations
Apo Apolipoprotein
AT1R Angiotensin II receptor, type 1
BOEC Blood outgrowth endothelial cells
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CAV Cardiac allograft vasculopathy
ECFCs Endothelial colony-forming cells
eNOS Endothelial nitric oxide synthase
EPC Endothelial progenitor cell
ERK Extracellular signal-regulated kinase
HDL High-density lipoprotein
ICAM Intercellular adhesion molecule
IDL Intermediate-density lipoprotein
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
IL Interleukin
IRI Ischaemia/reperfusion injury
JNK c-Jun N-terminal kinase
LDL Low-density lipoprotein
L-NAME L-NG-nitroarginine methyl ester
NADPH Nicotinamide adenine dinucleotide phosphate
NO Nitric oxide
p38 MAPK p38 mitogen-activated protein kinase
PI3K Phosphoinositide 3-kinase
S1P Sphingosine-1-phosphate
STAT3 Signal transducer and activator of transcription 3
SR-BI Scavenger receptor class B, type I
TBARS Thiobarbituric acid reactive substances
TLR4 Toll-like receptor 4
TNF-α Tumour necrosis factor-α
VCAM Vascular cell adhesion molecule
VEGF Vascular endothelial growth factor
VLDL Very-low-density lipoprotein
1 Introduction
Heart failure is the pathophysiological state in which cardiac dysfunction is respon-
sible for failure of the heart to pump blood at a rate commensurate with the
requirements of metabolising tissues. This clinical syndrome is characterised by
symptoms and signs of increased tissue and organ water and of decreased tissue and
organ perfusion. Heart failure is a growing public health problem, the leading cause
of hospitalisation and a major cause of mortality (Rathi and Deedwania 2012). The
prevalence of heart failure can be estimated at 2 % in the Western world, and the
incidence approaches 5–10 per 1,000 persons per year (Mosterd and Hoes 2007).
However, the prevalence and incidence progressively increase with age. The
prevalence of heart failure is 7 % in the age group 75–84 years and over 10 % in
those older than 85 years (Mosterd et al. 1999). Projections show that by 2030, the
Therapeutic Potential of HDL in Cardioprotection and Tissue Repair 529
prevalence of heart failure will increase 25 % from 2013 estimates (Go et al. 2013).
The 5-year age-adjusted mortality rates after onset of heart failure are 50 % in men
and 46 % in women (Roger et al. 2004).
Epidemiological studies support a strong association between high-density lipo-
protein (HDL) cholesterol levels and heart failure incidence. In Framingham Heart
Study participants free of coronary heart disease at baseline, low HDL cholesterol
levels were independently associated with heart failure incidence after adjustment
for interim myocardial infarction and clinical covariates (Velagaleti et al. 2009).
These seminal prospective data are in agreement with earlier cross-sectional studies
showing that post-infarct ejection fraction is lower in patients with low HDL
cholesterol levels (Kempen et al. 1987; Wang et al. 1998). Low HDL cholesterol
levels and low levels of apolipoprotein (apo) A-I, the main apo of HDL, indicate an
unfavourable prognosis in patients with heart failure independent of the aetiology
(Iwaoka et al. 2007; Mehra et al. 2009). An intriguing observation is that apo A-I is
expressed in the human heart and in the heart of human apo A-I transgenic mice
(Baroukh et al. 2004; Lowes et al. 2006).
The observed relationship between HDL and heart failure in epidemiological
studies might be due to residual confounding. Low HDL may be an integrated
biomarker of adverse metabolic processes including abnormal metabolism of
triglyceride-rich lipoproteins, insulin resistance, and ongoing tissue inflammation.
Crosstalk between inflammatory processes and metabolic dysregulation may be a
critical player in the pathogenesis of heart failure (Palomer et al. 2013). Here, we
will present experimental evidence from different angles, which support the view
that low HDL is unlikely an innocent bystander in the development of heart failure.
As will be discussed in the next sections, HDL exerts direct cardioprotective
effects, which are mediated via their interactions with the myocardium and more
specifically with cardiomyocytes (Sect. 2). HDL may improve cardiac function in
several ways. Firstly, HDL may protect the heart against ischaemia/reperfusion
injury resulting in a reduction of infarct size and thus in myocardial salvage
(Sect. 3). Secondly, HDL can improve cardiac function in the absence of ischaemic
heart disease as illustrated by its beneficial effects in diabetic cardiomyopathy
(Sect. 4). Thirdly, HDL may improve cardiac function by reducing infarct expan-
sion and by attenuating ventricular remodelling (Sect. 7). Since this latter effect is
an example of the role of HDL in tissue repair, the reparative functions of HDL will
be further dealt with in Sect. 5 on HDL and endothelial progenitor cells (EPCs) and
in Sect. 6 on topical HDL therapy for cutaneous wound healing.
2 In Vitro Effects of HDL on Cardiomyocytes
HDL may exert an indirect protective influence on the heart derived from their
ability to limit atherosclerotic plaque formation, thus preventing myocardial ischae-
mia and loss of myocardial tissue in acute coronary syndromes. Data are now
accumulating to indicate that HDL have a more immediate and direct effect on
cardiomyocytes. Discussion of these direct effects in this section will provide a
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more complete picture of the cardioprotective role of these lipoproteins and will
also raise questions about the use of the HDL complex itself as a therapeutic agent.
Although HDL is found in plasma, they are also present in the interstitial space
in amounts that correspond to approximately 25 % of their plasma concentration
(Parini et al. 2006). It is therefore physiologically relevant to evaluate their direct
impact on cells. The direct impact of HDL on cardiomyocytes has mainly been
studied in two in vitro models: (1) rat neonatal cardiomyocytes and (2) adult mouse
cardiomyocytes. These models allow the investigation of the specific actions of
HDL on cardiomyocytes independent of the systemic parameters and of endothelial
cells whose activity is regulated by HDL. Although studies investigating the direct
role of HDL on cardiomyocytes are relatively limited, they all show a beneficial
impact of HDL. These protective effects have been attributed to the activation of
intracellular signalling cascades involved in pro-survival cell fate.
2.1 Effects of HDL in Rat Neonatal Cardiomyocytes
In cultured rat neonatal cardiomyocytes, HDL treatment inhibits the cytotoxic
effects induced by oxidative stress from glucose and growth factor depletion or
doxorubicin incubation. This protective effect has mainly been evaluated by its
capacity to counteract the proapoptotic signals such as caspase 3 activation and
DNA fragmentation (Frias et al. 2010; Theilmeier et al. 2006). HDL incubation
induces the phosphorylation of phosphoinositide 3-kinase (PI3K)/Akt, extracellular
signal-regulated kinase (ERK) 1/2, p38 mitogen-activated protein kinase (p38
MAPK), and the transcription factor signal transducer and activator of transcription
3 (STAT3) (Frias et al. 2009). Although the precise mechanism of action has not
been completely elucidated, experiments using specific inhibitors have defined their
role in counteracting apoptotic signals induced by doxorubicin. These studies
suggest that the cardioprotective effect involves the activation of the pro-survival
proteins ERK1/2 and STAT3, but not p38 MAPK. HDL also induces the phosphor-
ylation of connexin 43 (Morel et al. 2012). This phosphorylation leads to a
reduction in gap junction permeability, which may limit the spread of mediators
implicated in death pathways. Connexin 43 phosphorylation requires the activation
of protein kinase C (Morel et al. 2012). Although there is not yet direct proof of the
implication of connexin 43 in the protective effects of HDL, connexin 43 has been
shown to be implicated in ischaemic conditioning (Schulz et al. 2007; Schulz and
Heusch 2004).
2.2 Adult Mouse Cardiomyocytes
In mouse adult cardiomyocytes, the protective actions of HDL have been
demonstrated using a model of hypoxia and reperfusion. Incubation of
cardiomyocytes with HDL before the hypoxia period (preconditioning) improved
cell survival (Frias et al. 2013). This protection involves the preservation of
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mitochondrial integrity, as HDL treatment inhibits mitochondrial permeability
transition pore opening. Similarly to the results obtained in neonatal
cardiomyocytes, HDL induces that activation of intracellular signalling pathways
such as PI3K/Akt, ERK1/2, and STAT3, which play a role in this protection. This
protective action of HDL is significantly inhibited in cardiomyocytes from
cardiomyocyte-restricted STAT3 knockout mice (Frias et al. 2013). Similarly,
cardiomyocytes treated with HDL after hypoxia (at reperfusion) show improved
cell survival compared to non-treated cells. In this context, the effects of HDL were
attributed to PI3K/Akt and ERK1/2 (Tao et al. 2010). The possible role of STAT3
has not been investigated in this reperfusion protocol.
Taken together, HDL-induced activation of several target proteins in
cardiomyocytes appears to be cardioprotective. These beneficial effects cannot be
attributed to its role in cholesterol transport.
2.3 Apo A-I and Sphingosine-1-Phosphate Mediate
the Cytoprotective Effects of HDL
As mentioned above, HDL can modulate the activation of signalling pathways
in cardiac cells. HDL is a complex particle, which is composed of numerous
proteins and bioactive lipids. Among these constituents, apo A-I and sphingosine-
1-phosphate (S1P) are the two major effectors that have been involved in the
activation of signalling pathways. Activation occurs via the binding of the HDL
particle to scavenger receptor class B, type I (SR-BI), and of S1P to S1P receptors.
S1P binds to five (S1P1–S1P5) high-affinity G protein-coupled receptors generating
multiple downstream signals. Of the different S1P receptor subtypes, only S1P1,
S1P2, and S1P3 receptors are expressed in the heart (Means and Brown 2009). S1P
has been shown to be cytoprotective and to confer cardioprotection. For a more
detailed discussion of the cardioprotective role of S1P, the interested reader is
referred to recent reviews (Karliner 2013; Sattler and Levkau 2009).
In vitro, most of the beneficial effects of HDL mentioned above have been
attributed to S1P. Data from experiments using pharmacological antagonists spe-
cific for S1P1, S1P2, and S1P3 receptors demonstrate an inhibition of the HDL
actions. For example, several experiments suggest that S1P3 is involved in PI3K/
Akt signalling and that S1P2 and/or S1P1 might be involved in ERK1/2 and STAT3
signalling (Frias et al. 2009; Tao et al. 2010). S1P2 was shown to play a key role in
the HDL-induced protection against the apoptotic effects of doxorubicin (Frias
et al. 2010). In the protection against hypoxia reperfusion injury, a predominant,
mediatory role was indicated for the S1P1 and S1P3 receptors, via ERK1/2 and
PI3K/Akt activation. No role was attributed to S1P2, but neither was it investigated
(Tao et al. 2010). The evidence that reinforces the cytoprotective role of S1P comes
from experiments, where addition of S1P to reconstituted HDL (rHDL) containing
apo A-I improved the protection against the apoptotic action of doxorubicin (Frias
et al. 2010).
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It should be acknowledged that S1P cannot freely circulate in plasma and that
the major plasma lipoprotein source of this lipid is HDL. Therefore, it is not
surprising that the effects of HDL can be mediated by S1P. However, conflicting
data suggest S1P-independent effects of apo A-I. One explanation proposed
initially by Nofer and colleagues (2004) is that SR-BI can anchor the HDL particle
at the cell membrane and allow S1P to interact with its specific receptors. In this
context, Means and colleagues (Means et al. 2008) have shown that S1P1 is present
in lipid raft structures from adult mouse cardiomyocytes. Lipid rafts are known to
harbour SR-BI (Babitt et al. 1997). Although increasing evidence suggests a major
role of S1P, the mechanism of signal transduction from HDL particle to cell is still
under intensive investigation, and a possible role of SR-BI cannot be eliminated.
Crosstalk between intracellular signalling pathways increases the complexity of
the regulation of HDL-induced cascades and impedes identification of the specific
role of HDL constituents. Nevertheless, it is important to keep in mind that such
complexity can result in differing and conflicting data. Further investigations will
be necessary to elucidate the precise mechanism of action of HDL in
cardiomyocytes in vitro.
3 HDL Confer Protection Against Ischaemia Reperfusion
Injury
Whereas the previous section was dedicated to HDL-induced signalling in
cardiomyocytes and to cytoprotective effects of HDL in vitro, the role of HDL in
this section is extended to cardiac ischaemia/reperfusion injury (IRI).
Ischaemic heart disease is the leading cause of death in the world. After
myocardial infarction, early reperfusion is the most effective strategy to limit cell
death and subsequent complications that can lead to heart failure. However,
re-establishing perfusion is paradoxically detrimental to the heart, giving rise to
IRI. This phenomenon is termed lethal reperfusion injury and is defined as a
myocardial injury caused by the restoration of coronary flow after an ischaemic
episode. This injury culminates in the death of cardiomyocytes that were viable
immediately before the myocardial reperfusion. Combating IRI is a notable focus of
attempts to improve treatment strategies.
Experimental animal models of IRI are adequate to investigate the precise
mechanisms of action and the potential targets of therapeutic drugs. Most
investigations used the isolated rodent heart (ex vivo model) or transient ligature
of the left anterior descending coronary artery (in vivo model). All studies that
evaluated the effects of HDL on the heart submitted to the IRI protocol are
unanimous and demonstrate a beneficial effect on cardiac function. Among these
studies, a few demonstrated similar effects using rHDL, composed of apo A-I and
phospholipids (palmitoyl-oleoyl-phosphatidylcholine). Some studies used rHDL
containing the apo A-I Milano mutant.
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3.1 IRI in the Isolated Heart Model
An early study using HDL perfusion in isolated hearts suggested that HDL signifi-
cantly reduced post-ischaemic arrhythmias (Mochizuki et al. 1991). In contrast,
perfusion with low-density lipoproteins (LDL) had no effects indicating HDL
specificity. The mechanism was not defined, but it was hypothesised that the
lipoprotein stabilised bioactive arachidonic acid metabolites (Mochizuki
et al. 1991). These antiarrhythmogenic effects were later confirmed in vivo when
treatment with rHDL decreased the incidence of post-ischaemic arrhythmias
(Imaizumi et al. 2008). Surprisingly, treatment with apo A-I or phospholipids did
not significantly reduce these arrhythmogenic responses. The effect of rHDL was
mediated via the production of nitric oxide (NO), through an Akt/ERK/NO pathway
in endothelial cells (Imaizumi et al. 2008). Unfortunately, the direct impact on
cardiomyocytes was not investigated.
The direct cardioprotective impact of HDL on IRI has been studied by Calabresi
and colleagues (Calabresi et al. 2003). They reported that treatment with rHDL
improved post-ischaemic functional recovery and decreased creatine kinase release
in the coronary effluent. Lipid-free apo A-I or phosphatidylcholine liposomes were
not effective in protecting the heart from IRI. rHDL caused a dose-dependent
reduction of ischaemia-induced cardiac tumour necrosis factor-α (TNF-α) expres-
sion and content, which correlated with the improved functional recovery
(Calabresi et al. 2003). In agreement with this prior study, rHDL improved cardiac
function (Rossoni et al. 2004) and reduced infarct size compared to non-treated
animals (Gu et al. 2007). Recent studies showed that treatment with HDL signifi-
cantly reduced the infarct size in rodents submitted to IRI compared to non-treated
IRI animals (Frias et al. 2013; Morel et al. 2012). The protective impact of HDL or
rHDL did not depend on the timing of injection. Indeed, the treatment at the
moment of reperfusion was also effective, but to a lesser extent than the treatment
before the ischaemic period.
The precise mechanism of HDL-induced cardioprotection is under intensive
investigation, and the activation of intracellular signalling pathways plays an
important role in such cardioprotection. In this context, the protective role of
STAT3, previously shown in cardiomyocytes, has been confirmed in the isolated
heart model. The reduction of the infarct size induced by HDL was significantly
inhibited in STAT3 knockout mice (Frias et al. 2013). Mitochondria play an
important role in cell survival and may be the key player in cardioprotection.
Interestingly, HDL and rHDL containing apo A-I Milano have been shown to
preserve mitochondrial integrity (Frias et al. 2013; Marchesi et al. 2008), consistent
with a direct impact of HDL and rHDL on cardiac cells.
3.2 IRI in In Vivo Models
The data obtained ex vivo were extended to in vivo models. The first in vivo data on
cardiac function after HDL injection demonstrated that HDL injection stimulates
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myocardial perfusion. This effect was mediated via the activation of endothelial
nitric oxide synthase (eNOS) (Nofer et al. 2004). Although this study did not
investigate IRI, it underlines the potential response of the heart to HDL in vivo.
The effect of HDL was extended to an in vivo transient ligature of the left anterior
descending coronary artery model (Theilmeier et al. 2006). One single injection of
native HDL before ischaemia reduced infarct size, apoptotic cell death, and neutro-
phil infiltration. These protective effects were also significantly inhibited in the
presence of the eNOS inhibitor L-NG-nitroarginine methyl ester (L-NAME) and
were partially inhibited in S1P receptor subtype 3 KOmice (Theilmeier et al. 2006).
Taken together, these results suggest that the HDL action is mediated via NO
production and is dependent on the S1P content of HDL.
Similarly to the results obtained in the isolated heart, the protective role of rHDL
containing apo A-I Milano during ischaemia or at reperfusion significantly reduced
the infarct size induced by IRI in rabbits (Marchesi et al. 2004). Protective effects of
apo A-I were also demonstrated (Gu et al. 2007). Injection of apo A-I 10 min before
reperfusion significantly improved cardiac function, which was associated with a
reduction of myocardial TNF-α and interleukin (IL)-6 levels. Histological analysis
of cardiac tissue from rats treated with apo A-I showed a decrease in intercellular
adhesion molecule (ICAM) expression and neutrophil infiltration compared to
non-treated animals (Gu et al. 2007). It should be acknowledged that apo A-I and
rHDL can absorb phospholipids, including S1P, in plasma. This could modulate
their impact on IRI.
3.3 Apo A-I and S1P Confer Cardioprotective Effects on HDL
Based on all published reports, it is not easy to delineate the precise role of S1P or
apo A-I in the cardioprotective effects of HDL. Both constituents have been
investigated individually, and both have been shown to protect against IRI individ-
ually. However, their precise impact on the actions of HDL has not always been
investigated in the same study or in the same model. Interestingly, levels of
HDL-associated S1P were diminished in patients with coronary artery disease
(Sattler et al. 2010). Very recent data demonstrate a key role of apolipoprotein M
(apoM) in S1P binding to HDL particles (Christoffersen et al. 2011). Indeed, the
amount of S1P contained in HDL was very low in apoM KO and higher in apoM
overexpressing mice. Unfortunately, IRI in these mice has not yet been investigated.
With respect to S1P, given that its plasma concentration is many times higher
than its affinity for S1P receptors, it has been suggested that HDL might play the
role of neutralising and limiting the actions of circulating S1P (Murata et al. 2000).
The impact of S1P association with HDL on the function of HDL still remains to be
elucidated. It is probable that in the HDL particle, both are necessary to obtain the
maximal positive response.
The mechanisms of HDL-induced cardioprotection against IRI are complex and
cannot be attributed to the role of HDL in reverse cholesterol transport. More
precise knowledge on the role of different HDL constituents in intracellular
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signalling and cardioprotection would help to design a therapeutic compound,
which replicates all the beneficial aspects of HDL in the heart. Figure 1 illustrates
conceptually the direct actions of HDL on cardiomyocytes.
4 Human Apo A-I Gene Transfer Attenuates Diabetic
Cardiomyopathy
Diabetic cardiomyopathy is a cardiac disorder, which takes place in the absence of
coronary artery disease and hypertension, and is characterised by impaired left
ventricular function due to cardiac inflammation, oxidative stress, cardiomyocyte
apoptosis, cardiac perivascular and interstitial fibrosis, intramyocardial
microangiopathy, endothelial dysfunction, disturbed cardiac substrate metabolism,
cardiomyocyte hypertrophy, abnormal intracellular Ca2+ handling, and impaired
functionality of cardiac stem cells. This cardiac entity has first been recognised by
Rubler et al. (1972), and its existence has been confirmed during the last three
decades via epidemiological, clinical, and experimental studies. Hyperglycaemia,
hyperinsulinaemia, and dyslipidaemia each contribute to the pathogenesis of dia-
betic cardiomyopathy via triggering cellular signalling and subsequent specific
alterations in cardiac structure. However, hyperglycaemia-induced oxidative stress
has been proposed to be the key determinant in the development of diabetic
cardiomyopathy. Left ventricular diastolic dysfunction represents the earliest pre-
clinical manifestation of diabetic cardiomyopathy, preceding systolic dysfunction,
which can progress to symptomatic heart failure (Cosson and Kevorkian 2003;
Freire et al. 2007; Raev 1994).
Fig. 1 Proposed protective intracellular signalling pathways induced by HDL in cardiomyocytes.
HDL induces the activation of intracellular signalling pathways in cardiomyocytes. This activation
leads to cardioprotection. Most of the activated signalling pathways induced by HDL involve its
S1P constituent (HDL-S1P) and the participation of S1P receptor subtypes. Further investigations
are necessary to elucidate the precise role of SR-BI in cardioprotection induced by HDL. The
arrows indicate intracellular signalling as described in cardiomyocytes. Cx 43; connexin 43; PKC
protein kinase C; MEK1/2: ERK (MAPK) kinase 1/2
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HDLs have antidiabetic properties. They reduce hyperglycaemia via their capac-
ity to decrease pancreatic β-cell apoptosis (Abderrahmani et al. 2007; Fryirs
et al. 2010; Rutti et al. 2009) and to stimulate glucose disposal in skeletal muscle
(Han et al. 2007). They decrease dyslipidaemia via lowering adipocyte lipolysis
(Van Linthout et al. 2010a) and induce insulin sensitivity (Berg et al. 2001) via
upregulating the expression of adiponectin (Van Linthout et al. 2010a), which
abrogates the development of hyperinsulinaemia. Consequently, increased HDL
may, from a theoretical point of view, antagonise the main triggers of diabetic
cardiomyopathy.
The main hallmarks of diabetic cardiomyopathy, including cardiac oxidative
stress, interstitial inflammation, apoptosis, fibrosis, and endothelial dysfunction, on
the one hand and the pleiotropic effects of HDL on the other hand further support
the hypothesis that an increase in HDL may reduce the development of diabetic
cardiomyopathy (Fig. 2). Via a human apo A-I gene transfer strategy, this
Fig. 2 HDL reduces the development of diabetic cardiomyopathy. Type 2 diabetes mellitus is
associated with hyperglycaemia, dyslipidaemia, and hyperinsulinaemia. Hyperglycaemia is the
main trigger that contributes to the development of diabetic cardiomyopathy via the induction of
oxidative stress. Hallmarks of diabetic cardiomyopathy are, besides cardiac oxidative stress,
cardiac fibrosis, inflammation, apoptosis, and endothelial dysfunction, which reciprocally affect
one another (interconnected grey lines). HDLs have antidiabetic features (dotted lines): they
reduce hyperglycaemia and dyslipidaemia via—among other mechanisms—their capacity to
decrease pancreatic β-cell apoptosis and adipocyte lipolysis, respectively, and they increase
insulin sensitivity via the induction of adiponectin, abrogating the development of hyperinsu-
linaemia. Besides interference with the triggers that lead to diabetic cardiomyopathy, HDLs reduce
the features of diabetic cardiomyopathy via their pleiotropic effects, including their anti-oxidative,
antifibrotic, anti-inflammatory, antiapoptotic, and endothelial-protective effects ( full lines)
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hypothesis has been evaluated in an experimental rat model of streptozotocin-
induced diabetes mellitus associated with severe hyperglycaemia and an LDL to
HDL ratio of 1:1 (Van Linthout et al. 2007; Young et al. 1988).
4.1 Human Apo A-I Gene Transfer Influences Metabolic
Parameters in Streptozotocin-Induced Diabetes Mellitus
Apo A-I transfer resulted in a 60 % increase in HDL cholesterol, which was
paralleled with a significant decline in very-low-density lipoprotein (VLDL) cho-
lesterol, intermediate-density lipoprotein (IDL) cholesterol, and triglycerides,
whereas LDL cholesterol was unaffected (Van Linthout et al. 2008). Despite the
well-described antidiabetic effects of HDL involving their ability to reduce pancre-
atic β-cell apoptosis (Abderrahmani et al. 2007; Fryirs et al. 2010; Rutti et al. 2009),
apo A-I transfer did not reduce blood glucose levels (Van Linthout et al. 2008),
potentially due to the severity of the streptozotocin model, which is associated with
a remaining insulin production below 1 % (Hughes et al. 2001). The decline in
triglycerides and in the triglyceride-rich lipoproteins VLDL and IDL (Sztalryd and
Kraemer 1995) after apo A-I transfer suggests an HDL-mediated decrease in
lipolysis in adipose tissue, leading to less free fatty acids in the circulation, less
triglyceride synthesis in the liver, and subsequent less VLDL and IDL synthesis
(Tunaru et al. 2003). This hypothesis is corroborated by the ability of HDL to
reduce the expression of hormone-sensitive lipase (Van Linthout et al. 2010a), the
rate-limiting enzyme of adipocyte lipolysis in abdominal fat (Sztalryd and Kraemer
1995), and to increase the phosphorylation of the PI3K downstream target Akt in
abdominal fat (Van Linthout et al. 2010a). Akt is involved in the anti-lipolytic and
lipogenic effects of insulin in adipose tissue (Whiteman et al. 2002) and in the
regulation of the expression of the adipokine adiponectin (Cong et al. 2007; Pereira
and Draznin 2005), which is known to improve insulin sensitivity under diabetes
(Peterson et al. 2008). However, an involvement of HDL in the hepatic expression
of genes involved in triglyceride metabolism may not be excluded. The decrease in
cardiac glycogen content (Van Linthout et al. 2008) suggests that apo A-I transfer in
streptozotocin rats partly restored glucose metabolism as an energy source in the
heart instead of nearly exclusive reliance on fatty acid metabolism for production of
ATP (Kota et al. 2011).
4.2 Human Apo A-I Gene Transfer Attenuates Diabetes-
Associated Oxidative Stress, Cardiac Fibrosis,
and Endothelial Dysfunction
Hyperglycaemia induces oxidative stress via creating a disbalance between the
generation of reactive oxygen species and their resolution by antioxidant enzymes,
like superoxide dismutases, which convert O2
 anions into molecular oxygen and
hydrogen peroxide (Nishikawa et al. 2000). Reactive oxygen species initiate diverse
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stress-signalling pathways including ERK, c-Jun N-terminal kinase (JNK),
and p38 MAPK, alter cellular proteins, and induce lipid peroxidation. In
diabetic cardiomyocytes, reactive oxygen species are predominantly generated
by mitochondria, due to mitochondrial oxidation of fatty acids (Kota et al. 2011),
and by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases
(Li et al. 2010b). The pathological importance of p38 MAPK in the diabetic heart
follows from the observation that p38 MAPK inhibition reduces cardiac inflamma-
tion and improves left ventricular dysfunction in streptozotocin-induced diabetic
mice (Westermann et al. 2006). Besides decreasing the activity of p38 MAPK, apo
A-I transfer reduced cardiac oxidative stress via upregulating the expression of the
diabetes-downregulated mitochondrial superoxide dismutase-2 and extracellular-
superoxide dismutase (Van Linthout et al. 2008). Both forms of superoxide
dismutase are important for the heart as outlined in studies whereby cardiac
overexpression of superoxide dismutase-2 protected the mitochondrial respiratory
function and blocked apoptosis induction (Shen et al. 2006; Suzuki et al. 2002) and
overexpression of extracellular-superoxide dismutase decreased macrophage infil-
tration and fibrosis and improved left ventricular dysfunction (Dewald et al. 2003).
These studies postulate that the decrease in cardiac fibrosis after apo A-I transfer in
streptozotocin-diabetic rats can be partly explained by the reduction in oxidative
stress and inflammation, including downregulated expression of pro-fibrotic
cytokines (inflammatory fibrosis) (Tschope et al. 2005), as well as by the decrease
in cardiac apoptosis (cfr. supra) and subsequent replacement fibrosis, resulting in
improved left ventricular function. The anti-inflammatory and antifibrotic effects of
HDL are supported by findings in apo A-I knockout mice, which are associated with
increased inflammatory cells and collagen deposition in the lung (Wang et al. 2010),
and from observations with the mimetic apo A-I peptide 4F demonstrating an
L-4F-mediated decreased endothelial cell matrix production (Ou et al. 2005).
Since cardiac NADPH oxidases play a predominant role in the development of
diabetic cardiomyopathy (Guo et al. 2007; Wold et al. 2006) and in diabetic cardiac
remodelling (Li et al. 2010b), decreased cardiac NADPH oxidase activity following
apo A-I transfer (Van Linthout et al. 2009) may be a critical mediator of reduced
cardiac oxidative stress and subsequent fibrosis in the myocardium.
Systemically, apo A-I transfer decreased the oxidative stress in rats with
streptozotocin-induced diabetes as indicated by the decline in serum levels of
thiobarbituric acid reactive substances (TBARS) (Van Linthout et al. 2008), a
marker of lipid peroxidation (Tschope et al. 2005). This finding is corroborated
by Mackness et al. (1991), who reported that HDLs decrease the formation of
TBARS on oxidised LDL. This is likely mediated by an increase in the activity of
paraoxonase or platelet-activating factor-acetyl hydrolase, 2 enzymes with anti-
oxidative features, which are associated with HDL and which are known to be
induced after apo A-I gene transfer (De Geest et al. 2000).
In the vasculature of diabetic rats, apo A-I transfer decreased oxidative stress as
indicated by the reduction in diabetes-enhanced NADPH oxidase activity and
eNOS uncoupling (Van Linthout et al. 2009), a phenomenon occurring when
eNOS produces O2
 rather than NO. Uncoupling of eNOS is, besides NADPH
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oxidases (Cai 2005), an important source of reactive oxygen species in diseased,
including diabetic, blood vessels (Hink et al. 2001). Consistent with the
demonstrated role of the angiotensin II receptor, type 1 (AT1R) in mediating
increased NADPD oxidase activity, and eNOS uncoupling in diabetes (Oak and
Cai 2007), the downregulation in diabetes-induced AT1R (Hodroj et al. 2007; Nyby
et al. 2007) after apo A-I transfer (Van Linthout et al. 2009) was postulated to be the
predominant mediator of reduced NADPH oxidase activity and eNOS uncoupling.
This hypothesis is further supported by in vitro findings showing that the
HDL-mediated reduction in AT1R expression in human aortic endothelial cells
was associated with a decline in hyperglycaemia-induced oxidative stress and a
reduced responsiveness to angiotensin II (Van Linthout et al. 2009). These
observations underline the finding of Tolle et al. (2008), who showed that HDL
reduce NADPH oxidase-dependent reactive oxygen species generation via inhibi-
tion of the activation of Rac1, which is a downstream AT1R-dependent mediator of
angiotensin II (Ohtsu et al. 2006). The exact mechanism by which HDL affect
AT1R regulation under diabetes mellitus requires further fundamental studies.
However, since oxidised LDL (Li et al. 2000) and reactive oxygen species
(Gragasin et al. 2003) play a role in the induction of the AT1R in human aortic
endothelial cells, one may speculate that HDL via intrinsic anti-oxidative features
(cfr. supra, via paraoxonase and platelet-activating factor-acetyl hydrolase) may
contribute to the downregulation of the AT1R under diabetes mellitus, which
results in less NADPH oxidase activity and reactive oxygen formation and in turn
may decrease AT1R expression. Concomitant with the reduced vascular oxidative
stress, including decreased eNOS uncoupling, apo A-I transfer in streptozotocin rats
resulted in an enhanced NO bioavailability (Chalupsky and Cai 2005) and conse-
quently in a decrease in endothelial dysfunction (Van Linthout et al. 2009), which is
another hallmark of diabetic cardiomyopathy.
4.3 Human Apo A-I Gene Transfer Reduces Diabetes-Induced
Cardiac Inflammation
In agreement with the direct anti-inflammatory properties of HDL (Cockerill
et al. 2001; Hyka et al. 2001), apo A-I transfer decreased the diabetes-induced
intramyocardial inflammation (Westermann et al. 2007b, c) as indicated by the
reduction in ICAM-1, vascular cell adhesion molecule (VCAM)-1, and TNF-α
mRNA expression (Van Linthout et al. 2008) and VCAM-1 protein expression
(Van Linthout et al. 2010b). Downregulation of VCAM-1/ICAM-1 expression
suppresses monocyte-endothelial cell adhesion and subsequent transendothelial
migration of inflammatory cells. This in turn reduced local expression of cytokines
like TNF-α and consequently may attenuate the potentiation of the intramyocardial
inflammatory reaction. Hyperglycaemia (Li et al. 2010a; Piga et al. 2007), oxidised
LDL (Lee et al. 2010) (Hodgkinson et al. 2008; Peterson et al. 2007), and increased
angiotensin II (Alvarez et al. 2004; Rius et al. 2010) under diabetes mellitus
upregulate the expression of VCAM-1/ICAM-1. Since HDL did not affect blood
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glucose levels, the reduction in adhesion molecule expression was not an indirect
consequence of an HDL-mediated antidiabetic effect. However, the reduced levels
of TBARS, which are also retrieved on oxidised LDL, in diabetic rats treated with
apo A-I transfer compared to diabetic rats treated with control vector suggest that
apo A-I transfer decreases oxidised LDL and subsequent cardiac inflammation.
Oxidised LDLs are agonists of Toll-like receptor 4 (TLR4), which is expressed on
the cell surface of cardiac cells, including cardiomyocytes, smooth muscle cells,
and endothelial cells. A role for TLR4 in the development of diabetic cardiomyop-
athy has recently been suggested (Zhang et al. 2010). The documented
HDL-mediated reduction in endothelial TLR4 expression and subsequent decrease
in NF-κB activity (Van Linthout et al. 2011) suggest that the reduction in cardiac
inflammation after apo A-I transfer is further partly mediated via a decrease in
endothelial TLR4 expression, limiting oxidised LDL-endothelial TLR4 interactions
and subsequent activation of NF-κB. Furthermore, the activation of the AT1R,
whose expression is upregulated under diabetes mellitus (Cohen 1993; Nyby
et al. 2007), contributes to the development of diabetic cardiomyopathy. After all,
AT1R antagonism under diabetes mellitus improves endothelial function
(Cheetham et al. 2000) and reduces cardiac inflammation and fibrosis, resulting in
an improvement in cardiac function (Westermann et al. 2007a). The observations
that apo A-I transfer reduces aortic AT1R expression in streptozotocin-induced
diabetic rats and that HDLs decrease the hyperglycaemia-induced AT1R expression
in endothelial cells (Van Linthout et al. 2009) suggest that apo A-I transfer reduces
cardiac endothelial AT1R and subsequent angiotensin II responsiveness including
the induction of VCAM-1/ICAM-1 expression and subsequent monocyte-
endothelial cell adhesion (Alvarez et al. 2004; Rius et al. 2010). Downregulation
of the expression of the anti-inflammatory adipokine adiponectin (Ouchi
et al. 2000, 2001; Ouedraogo et al. 2007) as observed in diabetic patients and in
streptozotocin rats (Thule et al. 2006) has been implicated in chronic inflammatory
phenotype in these subjects/rats. The positive correlation between apo A-I/HDL
plasma levels and adiponectin concentrations (Verges et al. 2006) and the finding
that apo A-I transfer increases the expression of adiponectin in an experimental
model of extreme inflammation (Van Linthout et al. 2010a) further suggest that the
effects of HDL on adiponectin expression may contribute to its anti-inflammatory
effects and to the attenuation of cardiac inflammation in rats with streptozotocin-
induced diabetes. Finally, since apo A-I induces regulatory T cells (Wilhelm
et al. 2010), which protect against the pro-inflammatory status of endothelial cells
(He et al. 2010), an induction in regulatory T cells following apo A-I transfer may
also partly account for the reduced cardiac inflammation in diabetic rats.
Since inflammation triggers fibrosis (Ismahil et al. 2013; Savvatis et al. 2012;
Westermann et al. 2011), the less pronounced diabetes-induced cardiac fibrosis (cfr.
infra) following apo A-I transfer might partly be explained by the decrease in
cardiac inflammation. In this context, the influence of a systemic HDL-mediated
immunomodulation on cardiac inflammation and fibrosis needs further
investigation.
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4.4 Human Apo A-I Gene Transfer Reduces Diabetes-Associated
Cardiac Apoptosis and Improves the Cardiac Endothelial
Integrity
Cardiac apoptosis is another hallmark of diabetic cardiomyopathy. The incidence of
cardiac apoptosis is higher in diabetic patients (Frustaci et al. 2000) and in diabetic
animals (Cai et al. 2002) compared to non-diabetic controls and is directly linked to
hyperglycaemia-induced oxidative stress (Cai et al. 2002). Mitochondria play an
important role in oxidative stress-induced apoptosis. Caspase 3 and caspase 7 are
essential mediators in the mitochondrial processes of apoptosis (Lakhani
et al. 2006). In accordance with the reduction in oxidative stress, including the
upregulation of cardiac mitochondrial superoxide dismutase-2 expression, apo A-I
transfer decreased the induced caspase 3/7 activity in streptozotocin rats (Van
Linthout et al. 2008). Concomitantly, apo A-I transfer raised the ratio of the
antiapoptotic Bcl-2, a ‘guardian’ against mitochondrial initiation of caspase activa-
tion (Susin et al. 1996), towards the proapoptotic Bax. This ratio is a marker of
increased cardiomyocyte survival probability (Condorelli et al. 1999). Furthermore,
apo A-I transfer normalised the diabetes-reduced phosphorylation of the
pro-survival protein kinase B Akt (Montanari et al. 2005; Uchiyama et al. 2004)
and of its effector eNOS to levels found in non-diabetic hearts (Van Linthout
et al. 2008). This finding was further corroborated by experiments in
cardiomyocytes. HDL supplementation on cardiomyocytes in the presence of
in vitro hyperglycaemia reduced apoptosis in a PI3K- and NO-dependent manner
(Van Linthout et al. 2008). The antiapoptotic effects of apo A-I transfer were
reflected at ultrastructural level by a reduced number of cardiomyocytes with
swollen mitochondria and apoptotic bodies and a more intact endothelium and
basement membrane (Van Linthout et al. 2008). These findings and the presence of
activated Akt in cardiomyocytes, as well as in cardiac endothelial cells documented
via immunofluorescence staining, underscore the importance of Akt activation after
apo A-I transfer in the reduction of cardiomyocyte apoptosis as well as in the
improvement in endothelial integrity. The ameliorated integrity of the endothelium
suggests a potential restoration of the microvascular homeostasis, which has been
demonstrated to reduce cardiomyocyte apoptosis and to result in the recovery of
cardiac function in diabetic cardiomyopathy (Yoon et al. 2005). The significance of
the cardiac endothelium on the contractile state and Ca2+ handling of subjacent
cardiomyocytes (Brutsaert 2003; Nishida et al. 1993; Ramaciotti et al. 1992)
suggests that part of the HDL-mediated improvement in left ventricular function
in rats with streptozotocin-induced diabetes was indirectly due to their protective
effect on the cardiac endothelium. This hypothesis is supported by the improvement
in endothelial function found after apo A-I transfer in streptozotocin-induced
diabetic rats (Van Linthout et al. 2009). In addition, HDL supplementation on
isolated cardiomyocytes directly improved their contractility under
hyperglycaemia-induced stress in a PI3K- and NO-dependent manner (Van
Linthout et al. 2008).
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Besides the direct HDL-mediated cardiomyocyte-protective effects and the
endothelial-protective features, the decrease in cardiac apoptosis after apo A-I
transfer in diabetic rats might be attributed to several other in parallel
HDL-mediated triggered processes: (1) HDL may act as biological buffers capable
of rapidly removing active proapoptotic TNF-α from the heart; (2) they have the
potential to increase (Rossoni et al. 2004), stabilise, and activate prostaglandins
(Aoyama et al. 1990). This enhanced prostanoid availability/activity may contrib-
ute to the HDL-mediated cardioprotection, by acting directly on cardiomyocytes
(Zacharowski et al. 1999) and/or by inhibiting cardiac TNF-α production
(Shinomiya et al. 2001); (3) HDL may reduce the expression of TLR 4 (Van
Linthout et al. 2011), which has recently been shown to play an important role in
cardiac apoptosis in diabetic cardiomyopathy.
In conclusion, apo A-I transfer attenuates the development of experimental
diabetic cardiomyopathy via its anti-oxidative, anti-inflammatory, antifibrotic,
and antiapoptotic actions (Fig. 2). Beyond beneficial vascular/cardioprotective
long-term effects, direct myocardial effects of HDL may contribute to the improve-
ment of cardiac function under severe streptozotocin-induced stress. Further studies
are required to investigate the potential of apo A-I transfer to ameliorate established
diabetic cardiomyopathy, especially in the context of type 2 diabetes mellitus, and
to improve the function of HDL, which is impaired under diabetic conditions
(Hedrick et al. 2000; Persegol et al. 2006; Sorrentino et al. 2009; Zheng
et al. 2004). Finally, also the impact of the apo A-I/HDL-induced immunomodula-
tory effects on diabetes-associated endothelial dysfunction and cardiac fibrosis
needs further clarification.
5 HDL and Tissue Repair: Modulation of EPC Biology via
SR-BI
The term EPC is most often used in a very broad sense. There is no consensus
definition of EPCs, which is a major source of confusion in the literature. EPCs
encompass different categories of cells with different phenotypic and functional
properties that affect neovascularisation and reendothelialisation. In a narrow,
literally correct, and unambiguous sense, EPCs are immature precursor cells capa-
ble of differentiating into mature endothelial cells in vivo (Hagensen et al. 2010).
Thus, an EPC sensu stricto corresponds to an in vivo category and is defined from a
functional point of view. However, there are very significant methodological
challenges to detect incorporation of circulating progenitor cells in the endothelium
(Hagensen et al. 2010). Incorporation of EPCs is in general a relatively rare event
(Feng et al. 2008, 2009a, b; Hagensen et al. 2010). High-resolution multichannel
sequential confocal scanning microscopy provides a platform for colocalisation
analysis with high specificity, which is required in lege artis cell tracking studies
(De Geest 2009). Alternatively, EPCs may act in a paracrine way by releasing
angiogenic factors and proteases to stimulate sprouting of local vessels or promote
reendothelialisation indirectly (Rehman et al. 2003; Takakura et al. 2000; Urbich
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et al. 2005). To make a distinction with EPCs sensu stricto, these cells may be
designated as proangiogenic haematopoietic progenitor cells (Fig. 3).
Different protocols for short-term culture of blood mononuclear cells on fibro-
nectin (with or without gelatin)-coated plates have been established by Vasa
et al. (2001) and Hill et al. (2003). These cells are stimulated by in vitro culture
conditions to mimic many features of endothelial cells (Hirschi et al. 2008). How-
ever, the putative EPCs identified by these assays do not give rise to a lineage of
endothelial progeny, but cultured cells in these assays consist of monocytes or a
population of haematopoietic cells with monocyte-macrophage or T-cell lineage
commitment. Nevertheless, these so-called early EPCs or early outgrowth EPCs
may regulate the angiogenic response in a paracrine way (Hirschi et al. 2008). In
Fig. 3 Role of bone marrow-derived proangiogenic haematopoietic progenitor cells and EPCs
sensu stricto in endothelial repair and neovascularisation. Proangiogenic haematopoietic progeni-
tor cells, the in vivo equivalent of ‘early EPCs’, contribute to vascularisation and endothelial repair
indirectly by secreting paracrine factors such as VEGF, hepatocyte growth factor (HGF), granulo-
cyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor
(GM-CSF), placental growth factor (PLGF), and IL-8. These factors stimulate local endothelial
cell proliferation. On the other hand, EPCs sensu stricto enhance neovascularisation and endothe-
lial repair directly by incorporation into the endothelium. EPCs sensu stricto can be considered to
constitute the in vivo equivalent of ECFCs or BOECs (‘late outgrowth EPCs’). ECs endothelial
cells; SMCs smooth muscle cells
544 S. Van Linthout et al.
contrast, endothelial colony-forming cells (ECFCs) (also called ‘late outgrowth
EPCs’ or ‘blood outgrowth endothelial cells’ (BOECs)) are immature precursor
cells capable of differentiating into mature endothelial cells in vivo. They are
derived from long-term culture of adherent peripheral blood mononuclear cells in
endothelial conditions (‘late outgrowth EPCs’) and consist of colonies that display
a cobblestone morphology (Ingram et al. 2004). ECFCs express cell surface
antigens like primary endothelium, clonally propagate, can be replated into second-
ary and tertiary ECFCs, form capillary-like structures in vitro, and become endo-
thelial cells in vivo (Ingram et al. 2004). ECFCs display postnatal vasculogenic
activity upon transplantation in a matrix scaffold (Richardson and Yoder 2011).
ECFCs could be considered to be similar to EPCs sensu stricto: they have a
potential for postnatal vasculogenesis and endothelial repair at sites of endothelial
damage. However, one should always consider that cell categories that are defined
based on in vitro cell culture conditions have always a rather artificial character.
HDLs enhance EPC-mediated repair (Feng et al. 2008, 2009a, b; Tso
et al. 2006). The effect of HDL on EPC number, function, and incorporation occurs
via SR-BI (Feng et al. 2009b). Since HDLs have been demonstrated to increase
vascular endothelial growth factor (VEGF) production by early EPCs in vitro,
HDLs may improve reendothelialisation by its effects on these circulating
proangiogenic cells (Feng et al. 2011). On the other hand, HDLs also improve
ECFC function in vitro, and these effects are dependent on signalling via SR-BI,
ERKs, and NO and on increased β1 integrin expression (Feng et al. 2011). Taken
together, HDL exerts potent effects on different functional categories of EPCs via
SR-BI.
The endothelial-protective and endothelial-reparative properties of HDL may be
pathophysiologically and clinically relevant under conditions of high endothelial
turnover. In healthy individuals, the endothelial layer is renewed at a low replica-
tion rate of 0–1 % per day (Erdbruegger et al. 2006). In pathological conditions of
arteriosclerosis, endothelial turnover may be higher. Arteriosclerosis is a broad
term that encompasses all diseases that lead to arterial hardening, including native
atherosclerosis, post-injury neointima formation, cardiac allograft vasculopathy
(CAV), and vein graft atherosclerosis. Areas of low shear stress in human arteries
have an increased rate of endothelial turnover (Tricot et al. 2000). Augmented
endothelial turnover is also observed in atherosclerosis-prone areas in apo E/
mice (Foteinos et al. 2008). However, the highest degree of endothelial turnover is
likely observed after arterial injury, in allografts (Rahmani et al. 2006), and in vein
grafts. Although there is significant evidence that HDLs exert beneficial effects in
models of angioplasty- or injury-induced arteriosclerosis (Ameli et al. 1994; De
Geest et al. 1997; Shah and Amin 1992), we will focus here on allograft
vasculopathy and vein graft atherosclerosis.
Orthotopic heart transplantation is a well-established therapy for selected
patients with end-stage congestive heart failure. The long-term success of heart
transplantation is limited by CAV. EPC-mediated repair may inhibit the progres-
sion of CAV. Although CAV is primarily the result of chronic rejection,
non-immunological factors are modifiers of CAV progression. In the ‘response to
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injury’ concept of CAV, vascular lesions are considered to be the result of cumula-
tive endothelial injury both by alloimmune responses and by non-alloimmune
insults (Vassalli et al. 2003). T-cell alloimmunity, antibody-mediated immune
attack, and non-immune factors induce endothelial cell death or endothelial dys-
function. Since the endothelium regulates vascular tone, inflammation, smooth
muscle cell proliferation, and thrombosis (Behrendt and Ganz 2002), restoration
of endothelial integrity and function is pivotal to attenuate the development of CAV
(Pinney and Mancini 2004). Markers of endothelial injury have been shown to
discriminate between CAV-positive and CAV-negative heart transplant recipients
(Singh et al. 2012), which is consistent with a postulated pivotal role of endothelial
injury in the pathogenesis of CAV.
Current strategies to prevent or treat CAV are clearly insufficient. Disruption of
the endothelial lining due to endothelial cell apoptosis can be restored by prolifera-
tion of adjacent endothelial cells but also by incorporation of circulating bone
marrow-derived EPCs (Friedrich et al. 2006; Walter et al. 2002; Werner
et al. 2002, 2003). Hu et al. (2003) have demonstrated that EPCs contribute to
endothelial regeneration in murine allografts. Moreover, increased HDL induced by
hepatocyte-directed human apo A-I gene transfer in C57BL/6 apo E/ mice
enhanced the incorporation of bone marrow-derived EPCs into the injured endo-
thelium of allografts from donor BALB/c mice and reduced neointima formation in
these allografts (Feng et al. 2008). In subsequent experiments using BALB/c
allografts in wild-type C57BL/6 mice, it was demonstrated that increased EPC
incorporation and attenuation of allograft vasculopathy induced by hepatocyte-
directed human apo A-I gene transfer are strictly dependent on SR-BI expression
in bone marrow and bone marrow-derived cells. This conclusion was reached based
on experiments in mice transplanted with wild-type bone marrow or alternatively
with SR-BI/ bone marrow. These data suggest that the effect of HDL on EPC
incorporation and/or paracrine effects of EPCs are critical for the attenuation of
allograft vasculopathy in this model. Nevertheless, the implications of these data
for clinical CAV are unknown since murine experiments are performed in the
absence of immunosuppressive therapies.
Surgical revascularisation using autologous vein grafts is limited by vein graft
failure, which is frequently due to an aggressive form of atherosclerosis (Campeau
et al. 1984). Vein graft failure is observed in 30–50 % of coronary bypass grafts
within 10 years (Fitzgibbon et al. 1996). Hypercholesterolaemia is a risk factor for
vein graft failure (Goldman et al. 2004), which may be related to adverse effects on
endothelial integrity and function (Raja et al. 2004). Previously, it has been
demonstrated that endothelial regeneration is retarded, and neointima formation is
accelerated in vein grafts in hypercholesterolaemic apo E/ mice compared to
normocholesterolaemic controls (Dietrich et al. 2000; Xu et al. 2003). Topical HDL
therapy reduced vein graft atherosclerosis in apo E/ mice (Feng et al. 2011).
Topical HDL application involves formulation of HDL in 20 % pluronic F-127 gel
(pH 7.2) (Feng et al. 2011). Pluronic F-127 is a biocompatible and non-toxic
substance and is characterised by thermoreversible gel formation at temperatures
above 21 C (Hu et al. 1999). One of the main advantages of topical HDL therapy is
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that the ‘distribution volume’ of the therapeutic agent is small compared to sys-
temic administration. In addition, the extracellular protein concentration of HDL is
300–400 μg/ml (Parini et al. 2006; Sloop et al. 1987). This is approximately 20 % of
the plasma protein concentration. Therefore, therapeutic effects of topical HDL can
be expected at HDL concentrations that are substantially lower than the plasma
concentration. Topical HDL administration on the adventitial side of vein grafts
improved vein graft patency and function (Feng et al. 2011). Caval veins of C57BL/
6 apo E/ mice were grafted to the right carotid arteries of recipient C57BL/6
TIE2-LacZ/apo E/ mice. HDL in 20 % pluronic F-127 gel was applied on the
adventitial side of vein grafts. Topical HDL application reduced intimal area by
55 % ( p< 0.001) at day 28 compared to control mice. Blood flow quantified by
micro-magnetic resonance imaging at day 28 was 2.8-fold ( p< 0.0001) higher in
grafts of topical HDL-treated mice than in control mice. Topical HDL potently
reduced intimal inflammation and resulted in enhanced endothelial regeneration as
evidenced by an increase in the number of CD31-positive endothelial cells. As
stated supra, HDL potently enhanced migration and adhesion of ECFCs in vitro,
and these effects were dependent on signalling via SR-BI, ERK, and NO and on
increased β1-integrin expression. Correspondingly, the number of CD31
β-galactosidase double-positive cells, reflecting incorporated circulating progenitor
cells, was 3.9-fold ( p< 0.01) higher in grafts of HDL-treated mice than in control
grafts. Importantly, the effects of topical HDL therapy on vein graft atherosclerosis
were similar compared to the effects of systemically increased HDL cholesterol
after human apo A-I gene transfer. Taken together, topical HDL application is a
new paradigm of HDL therapy.
Whereas this section was focused on HDL- and EPC-mediated endothelial
repair, the next two sections will deal with HDL and tissue repair. In these
therapeutic areas, the effect of HDL on EPCs may be an important mediator of
the beneficial effects of HDL-targeted therapies.
6 Development of Topical HDL Therapy for Cutaneous
Wound Healing
Wound healing results from complex interactions between extracellular matrix
molecules, soluble mediators, resident skin cells, and infiltrating leukocytes as
well as infiltrating EPCs. Rather artificially, wound healing can be divided in an
inflammation phase, a phase of tissue formation with accumulation of granulation
tissue and reepithelialisation, and finally a phase of tissue remodelling (Diegelmann
and Evans 2004).
Granulation tissue contains tissue macrophages, fibroblasts, numerous new
vessels, and extracellular matrix molecules. Macrophages stimulate fibroplasia
and angiogenesis by secretion of various growth factors. Fibroblasts deposit and
remodel the extracellular matrix of wounds. Blood vessels are needed to provide
oxygen and nutrients, whereas extracellular matrix provides a conduit for cell
migration and cell ingrowth. Formation of granulation tissue starts a few days
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after injury and is mainly triggered by growth factors such as platelet-derived
growth factor and transforming growth factor-β, which stimulate fibroblast prolif-
eration and migration (Singer and Clark 1999). Fibroblasts start to deposit and
remodel extracellular matrix, which initially consists of fibronectin and hyaluronan
but is later on replaced by proteoglycans and type I and III collagens (Toriseva and
Kahari 2009). The formation of new blood vessels is a critical component of to
granulation tissue formation. Angiogenesis is initially induced by tissue destruction
and hypoxia and is subsequently stimulated by various molecules such as basic
fibroblast growth factor, VEGF, and transforming growth factor-β, secreted by
macrophages, keratinocytes, and endothelial cells. A role of EPCs in granulation
tissue formation is directly suggested by experiments demonstrating that cell
therapy with EPCs enhances wound healing in mice (Suh et al. 2005). The release
of various growth factors such as VEGF and platelet-derived growth factor by EPCs
appears to enhance wound healing (Suh et al. 2005). Reepithelialisation is the term
used to describe the appearance of a new epithelial layer on top of a healing skin
wound. It is dependent on the formation of a provisional wound bed matrix and
involves the migration and proliferation of keratinocytes, the differentiation and
stratification of new epithelium, and finally the reformation of the basement
membrane.
Typical chronic cutaneous wounds are diabetic ulcers, ischaemic ulcers, and
pressure ulcers. Diabetic ulcers occur in patients with type 1 and type 2 diabetes,
whereas ischaemic ulcers are observed in patients with peripheral arterial diseases.
Pressure ulcers occur in patients with paralysis or in other conditions that inhibit
movement of body parts. Pressure ulcers or decubitus wounds typically occur on
sacrum, shoulder blades, and heels. Several factors contribute to deficient wound
healing in patients with diabetes: deficient growth factor production (Galkowska
et al. 2006), impaired neovascularisation (Galiano et al. 2004b), attenuated
keratinocyte and fibroblast proliferation and migration (Gibran et al. 2002), and
altered balance between extracellular matrix accumulation and remodelling of the
extracellular matrix by matrix metalloproteinases (Lobmann et al. 2002). Foot
ulcers occur in a diabetic population with a prevalence of 5 % and lifetime
incidence of 15 % (Abbott et al. 2002; Muller et al. 2002). Even with lege artis
treatment, amputation is required in 14–24 % of cases. Every 30 s, a lower limb is
lost due to diabetes. Approximately 85 % of these amputations are preceded by an
ulcer. Mortality is up to 50 % in the first 3 years after amputation. Various studies
show that costs to treat diabetic foot ulcers are extremely high, especially if
hospitalisation is required (Matricali et al. 2007).
HDL may beneficially affect wound healing by accelerating resolution of
inflammation, by enhancing granulation tissue formation involving increased
EPC incorporation and increased paracrine effects of EPCs, and by accelerating
reepithelialisation. Keratinocytes express SR-BI, and SR-BI expression is
upregulated in dividing keratinocytes (Tsuruoka et al. 2002). Whereas in humans
healing is primarily the result of reepithelialisation and granulation tissue forma-
tion, wound healing in mice occurs predominantly by wound contraction
(Greenhalgh 2003). In the excisional wound healing model (Galiano
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et al. 2004a), a circular full-thickness wound is applied on the back of each mouse.
Subsequently, a silicone splint is fixed around the wound with nylon sutures to
counteract wound contraction. Consequently, wound healing in this model occurs
by granulation tissue formation and reepithelialisation from the border. Granulation
tissue formation and reepithelialisation were significantly delayed in C57BL/6 apo
E/ mice compared to C57BL/6 mice (Gordts et al. 2014). Topical administration
of HDL (protein concentration 800 μg/ml; volume 80 μl) formulated in 20 %
pluronic F-127 gel (pH 7.2) every 2 days on wounds in C57BL/6 apo E/ mice
significantly improved granulation tissue formation and reepithelialisation. Wound
healing in mice treated with topical HDL therapy was very similar compared to
C57BL/6 mice. Topical gel without HDL did not enhance wound healing.
Improved wound healing induced by topical HDL therapy was also observed in
C57BL/6 mice with streptozotocin-induced diabetes mellitus and in male type
2 diabetic leptin receptor-deficient mice (unpublished data).
Further preclinical studies are required to evaluate the robustness of this strategy
in other models of delayed wound healing. However, murine models of diabetic
wound healing differ in many respects to clinical diabetic wound healing. They do
not take into account that there is a significant degree of heterogeneity of ulcers in
patients with diabetes. Three categories can be discerned: ‘purely neurotrophic’
diabetic ulcers, ‘purely ischaemic’ ulcers in patients with diabetes, and poorly
healing ulcers in diabetic patients with microangiopathy. The ‘purely neurotrophic’
diabetic ulcers heal well after off-loading. The ‘purely ischaemic’ ulcers should be
treated with revascularisation strategies. Typically, diabetic ulcers in patients with
more pronounced microangiopathy and macroangiopathy are characterised by
defects in granulation tissue formation and constitute a potential therapeutic area
for HDL-targeted therapies. However, no murine model can adequately mimic
these chronic diabetic ulcers. Decubitus wounds constitute another target for topical
HDL therapy but lack of adequate animal models hinders preclinical development.
7 Beneficial Effects of Selective HDL-Raising Gene Transfer
on Cardiac Remodelling and Cardiac Function After
Myocardial Infarction in Mice
Loss of myocardial tissue following acute myocardial infarction results in a
decreased systolic ejection and increased left ventricular end-diastolic volume
and pressure. The Frank-Starling mechanism, implying that an increased
end-diastolic volume results in an increased pressure developed during systole,
may help to restore cardiac output. However, the concomitant increased wall stress
may induce regional hypertrophy in the non-infarcted segment, whereas in the
infarcted area expansion and thinning may occur. Experimental animal studies
show that the infarcted ventricle hypertrophies and that the degree of hypertrophy
is dependent on the infarct size (Anversa and Sonnenblick 1990). Taken together,
architectural remodelling is characterised by the formation of a discrete collagen
scar, ventricular dilatation, and ventricular hypertrophy. This process may continue
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for weeks or months until the distending forces are counterbalanced by the tensile
strength of the collagen scar. Remodelling post-myocardial infarction is complex
since it involves the infarct area, the infarct border zone, and the non-infarcted
myocardium (Sutton and Sharpe 2000). Following myocardial infarction, dyski-
netic bulging may occur in infarct area. The myocardial fibres contiguous to this
segment in the infarct border zone become exposed to a more pronounced increase
in wall stress because of the more prominent change in the radius of curvature
induced by the regional dilatation. Cardiomyocytes in the border zone of the infarct
become larger than cardiomyocytes in the remote area of the ventricle. This is
consistent with the view that the infarct-induced stress on the chamber walls is an
important determinant of cardiomyocyte hypertrophy (Cohn 1993).
Post-infarct remodelling occurs in the setting of volume overload, since the
stretched and dilated infarcted tissue increases the left ventricular volume. An
increased ventricular volume not only implies increased preload (passive ventricu-
lar wall stress at the end of diastole) but also increased afterload (total myocardial
wall stress during systolic ejection). Afterload is increased since the systolic radius
is increased. Since both systolic and diastolic wall stress are increased, remodelling
and hypertrophy post-myocardial infarction are characterised by mixed features of
pressure overload and volume overload.
The myocardium consists of 3 integrated components: cardiomyocytes, extra-
cellular matrix, and capillary microcirculation. All 3 components are involved in
the remodelling process. The role of the extracellular matrix is distinct in the early
phase of remodelling (within 72 h) and the late phase (beyond 72 h). Neutrophil
infiltration of matrix metalloproteinases induces degradation of intermyocyte col-
lagen struts and cardiomyocyte slippage. This leads to infarct expansion
characterised by the disproportionate thinning and dilatation of the infarct segment
(Erlebacher et al. 1984). Infarct expansion predisposes to myocardial rupture and
congestive heart failure (Eaton et al. 1979; Erlebacher et al. 1982; Jugdutt and
Michorowski 1987; Schuster and Bulkley 1979). Increased wall stress as a result of
infarct expansion leads to mechanical stretch-elicited local angiotensin II release
and activation of a fetal gene programme (Sutton and Sharpe 2000). Local angio-
tensin II release promotes cardiomyocyte hypertrophy. In later stages of
remodelling, interstitial fibrosis is induced. Transforming growth factor-β1
transforms fibroblasts into myofibroblasts and induces activation of tissue inhibitors
of metalloproteinases and production of type I and type III collagen. The resultant
interstitial fibrosis negatively affects the diastolic properties of the heart.
Post-infarct ejection fraction is lower in patients with low HDL cholesterol
levels (Kempen et al. 1987; Wang et al. 1998). Although this could be due to
differences in atherosclerosis or in the microvasculature or could be related to a
decrease in infarct size due to beneficial effects of HDL in IRI, the possibility that
HDL beneficially affects infarct expansion and ventricular remodelling should be
considered. This can be investigated in models of permanent ligation of, e.g. the left
anterior descending coronary artery. An attenuation of post-infarct left ventricular
remodelling and improved infract healing was induced by infusion of rHDL once a
week for 4 weeks in rats following ligation of the proximal left coronary artery
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(Kiya et al. 2009). Interestingly, rHDL-treated rats also showed an increase of
phosphorylation of ERK1/2 in the left ventricular tissue, but not of p38 MAPK or
JNK (Kiya et al. 2009). Gordts et al. (2013) have recently shown that human apo
A-I gene transfer in C57BL/6 LDL receptor-deficient mice increases survival,
decreases infarct expansion, attenuates left ventricular dilatation, and improves
cardiac function following permanent ligation of the left anterior descending
coronary artery. Gene transfer in C57BL/6 LDL receptor-deficient mice was
performed with the E1E3E4-deleted adenoviral vector AdA-I, inducing
hepatocyte-specific expression of human apo A-I, or with the control vector Adnull.
A ligation of the left anterior descending coronary artery was performed 2 weeks
after transfer or saline injection. Permanent ligation of the left anterior descending
coronary artery excludes salutary coronary effects of HDL on myocardial salvage
as observed in models of IRI (Theilmeier et al. 2006). Consequently, the infarct area
and the area at risk were nearly identical at 24 h after ligation implying that the
initial increase in loading conditions was not different between human apo A-I gene
transfer myocardial infarction mice and control myocardial infarction mice. HDL
cholesterol levels were persistently 1.5 times ( p< 0.0001) higher in AdA-I mice
compared to controls. Survival was increased ( p< 0.01) in AdA-I myocardial
infarction mice compared to control myocardial infarction mice during the
28-day follow-up period (hazard ratio for mortality 0.42; 95 % CI 0.24–0.76).
Longitudinal morphometric analysis demonstrated attenuated infarct expansion
(reduced infract length and increased infarct thickness of the infarct in AdA-I
myocardial infarction mice) and inhibition of left ventricular dilatation in AdA-I
myocardial infarction mice compared to controls. AdA-I transfer exerted immuno-
modulatory effects and increased neovascularisation in the infarct zone. Increased
HDL after AdA-I transfer significantly improved systolic and diastolic cardiac
function post-MI and led to a preservation of peripheral blood pressure.
The effects of AdA-I transfer on remodelling have significant consequences for
the progressive development of heart failure. Ventricular dilatation increases the
loading conditions of the heart. After all, ‘preload’ at the organ level corresponds to
passive ventricular wall stress at the end of diastole (preloadLV¼ (EDPLV)
(EDRLV)/2WTLV where EDP is end-diastolic pressure, EDR is end-diastolic radius,
and WT is wall thickness). ‘Afterload’ at the organ level reflects myocardial wall
stress during systolic ejection (afterloadLV¼ (SPLV) (SRLV)/2WTLV where SP is
systolic pressure, SR is systolic radius, and WT is wall thickness). Thus, the
attenuation of infarct expansion and ventricular dilatation induced by increased
HDL is critical for long-term preservation of left ventricular function. Although an
increase of end-diastolic volume may be physiologically beneficial in terms of the
Frank–Starling mechanism, the increase in afterload in a larger ventricle is clearly
not beneficial. The increase in afterload corresponds at the cellular level to an
increase in tension that each muscle fibre must develop, and correspondingly,
oxygen consumption increases. In addition, ventricular hypertrophy may be
associated with an imbalance between the vascular and cardiomyocyte compart-
ment in the myocardium (Shimizu et al. 2010; Tirziu et al. 2007). Increased oxygen
consumption together with a decrease in relative vascularity may lead to tissue
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hypoxia, cardiomyocyte dysfunction, and late cardiomyocyte death. There was a
trend for a higher capillary density and a higher relative vascularity at day 28 in
AdA-I myocardial infarction mice compared to control myocardial infarction mice.
Taken together, ventricular dilatation initially produced by an external stimulus
(ligation of the left anterior descending coronary artery) induces a vicious cycle
where an increase of loading conditions leads to an intrinsic pathological heart
muscle (cardiomyopathy) characterised by cardiomyocyte death and dysfunction
(reduced intrinsic myocardial contractility and relaxation), collagen deposition, and
progressive dilatation of the heart. Although no follow-up was performed in the
current study after 28 days, we speculate that differences in ventricular function
between control MI mice and human apo A-I gene transfer MI mice will be more
marked after longer follow-up.
Neovascularisation may play a role in scar formation and scar tissue remodelling
(Wang et al. 2005). Increased neovascularisation was observed in the infarcts of
AdA-I myocardial infarction mice at day 28 after gene transfer. HDL exerts potent
effects on the endothelium. These effects occur via enhanced endothelial survival
(Nofer et al. 2001), endothelial cell migration (Seetharam et al. 2006), and
EPC-mediated repair (Feng et al. 2009a, b; Tso et al. 2006). Beneficial effects on
EPCs may have contributed to improved infarct healing.
Taken together, attenuation of remodelling following human apo A-I gene
transfer may be considered to constitute the cardiac equivalent of enhanced
wound healing and tissue repair induced by HDL.
Conclusions
One of the pitfalls in the field of HDL-targeted interventions is the lack of
selective HDL-raising drugs. The development of gene transfer technologies
with a sufficiently high therapeutic index may pave the road for a selective and
effective HDL-targeted therapeutic intervention (Jacobs et al. 2012; Van
Craeyveld et al. 2010). Nathwani et al. (2011) performed a landmark study
that demonstrated for the first time long-term expression of a transgene product
at therapeutic levels following systemic hepatocyte-directed gene transfer in
humans. In this study (Nathwani et al. 2011), haemophilia B was successfully
treated with an adeno-associated viral serotype 8 human FIX expressing vector.
These seminal data highlight that hepatocyte-directed adeno-associated viral
serotype 8 gene transfer may become a clinical reality in the next decades.
The recent positive assessment by the European Medicines Agency’s Committee
for Medicinal Products for Human Use of the marketing authorisation for the
first gene transfer product in Europe (alipogene tiparvovec (Glybera®))
highlights an important paradigm shift by regulatory agencies, as well as the
biotechnological entrepreneurs and investors. Nevertheless, there is no short-
term perspective for widespread clinical use of gene transfer technologies.
Three modalities discussed in this review are selective HDL-targeted
therapies: infusion of rHDL, human apo A-I gene transfer, and topical HDL
therapy. The main strategic questions with regard to HDL-targeted therapies are
related to the choice of therapeutic areas in which a real clinical difference could
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be made. These questions are inextricably linked to the current state of the art of
evidence-based medicine. Since a significant part of this review is focused on
heart failure, we will illustrate this point on the basis of a very significant
dichotomous classification of these patients.
Among patients with hospitalised heart failure, approximately 50 % have
heart failure with reduced ejection fraction (HFrEF), and 50 % have heart failure
with preserved ejection fraction (HFpEF) with the proportion of patients with
HFpEF increasing with time (Liu et al. 2013; Vaduganathan and Fonarow 2013).
The cutoff value for preserved ejection fraction is 0.5. Most clinical heart failure
trials have been focused on patients with HFrEF. Inhibition of the renin-
angiotensin-aldosterone and sympathetic nervous systems improves survival
and decreases hospitalisations in patients with HFrEF (Reed et al. 2014). In
contrast to these significant advances in treatment and reduction in mortality
in patients with HFrEF, drug strategies with strong evidence in HFrEF have
proved unsuccessful in HFpEF, and the mortality in patients with HFpEF has
remained unchanged (Liu et al. 2013). HFpEF is a complex clinical syndrome
that is characterised by classical heart failure symptoms with increased left
ventricular filling pressures and preserved left ventricular ejection fraction.
Increased end-diastolic ventricular stiffness is observed in HFpEF, but the
exact mechanisms that induce HFpEF are unknown. This heart failure subtype
disproportionately affects women and the elderly and is commonly associated
with other cardiovascular comorbidities, such as hypertension and diabetes.
Most therapeutic gains can likely be made in the field HFpEF. Interestingly,
human apo A-I gene transfer has been shown to improve diastolic function in
C57BL/6 LDL receptor-deficient mice (Gordts et al. 2012). The same strategic
questions should also be raised in relation to the role of HDL in prevention and
treatment of coronary artery disease. One might speculate that perspectives for
an HDL-targeted therapy in patients with stable coronary artery disease are
limited, whereas beneficial coronary and myocardial effects in the setting of
acute coronary syndromes may still constitute a window of opportunity.
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